|Mr. Thomas Liquard||Chief Exec. Officer||287.49k||N/A||45|
|Mr. Peter Anastasiou||Exec. Vice Chairman||40k||N/A||37|
|Dr. Jerry Kanellos Ph.D.||Chief Operating & Scientific Officer||163.97k||N/A||56|
|Mr. Phillip Allen Hains BBus(Acc), MBA, CA||Joint CFO & Company Sec.||N/A||N/A||58|
|Mr. Peter Vaughan BBus(Acc), CA||Joint CFO & Company Sec.||N/A||N/A||34|
Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle. The company markets and sells Travelan for the prevention of travellers diarrhea. Its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. The company also has other preclinical immunotherapy pipeline products targeting immune-related diseases. Immuron Limited has a research and development collaboration agreement with the Walter Reed Army Institute of Research (WRAIR) for the development of a Shigella vaccine; and Naval Medical Research Center for the testing of Travelan in cell lines of campylobacter and enterotoxigenic escherichia coli. The company was founded in 1994 and is based in Blackburn North, Australia.
Immuron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.